Hall A, September 8, 2014
Transkript
Hall A, September 8, 2014
2 3 Hall A, September 8, 2014 4 08:00-08:30 Registration 08:30-09:00 Opening Ceremony 09:00-09:45 A unifying PKPD relationship and its application in selecting the dose and dosing interval for a new nanoparticulate formulation Leslie Z. Benet - Plenary Lecture, University of California San Francisco, United States 09:45-10:15 Emerging concepts in dendrimer-based nanomedicine: translation to clinical applications. Donald A. Tomalia, Virginia Commonwealth University, United States 10:15-10:45 Non-biological complex drugs and nanosimilars: complexity is in the details Gerrit Borchard, University of Geneva, Switzerland 10:45-11:00 Coffee Break 11:00-11:30 An oral nano/microparticulate delivery system promotes intestinal absorption of drug loaded nanocapsules Simon Benita, The Hebrew University of Jerusalem, Israel 11:30-12:00 Nanoscale drug delivery systems and the blood-brain barrier Yılmaz Çapan, Hacettepe University, Turkey 12:00-12:30 Nanotechnology innovations for neurological disorders Sayed Moien Moghimi, University of Copenhagen, Denmark 12:30-14:00 Lunch 14:00-14:30 Nanotechnologies for lung delivery: efficacy and safety Elias Fattal, University of Paris-Sud, France 14:30-15:00 Nanoparticles for targeting ocular and renal tissue Achim Goepferich, University of Regensburg, Germany 15:00-15:30 Nanoenabled medicines cross challenging biological barriers Ijeoma F. Uchegbu, UCL School of Pharmacy, United Kingdom 15:30-16:00 Self assembly strategy for preparation of core-shell nanoparticles as anticancer drug carrier systems Katerina Goracinova, University “Sts Cyril and Methodius”, Macedonia 16:00-16:15 Coffee Break 16:15-16:45 Cationic coated nanoparticles for intravenous or oral administration in cancer chemotherapy Erem Bilensoy, Hacettepe University, Turkey 16:45-17:15 BASF Oleochemicals/ Improving Patient Compliance Cihan Sancaktaroğlu, BASF, Turkey 17:15-17:45 Formulation considerations for push/pull osmotic pumps Marcel Cimpan, Colorcon, United Kingdom 17:45-18:00 Oral Presentation-1 18:00-18:15 Oral Presentation-2 18:15-18:30 Oral Presenttaion-3 Hall B, September 8, 2014 14:00-14:30 Title to be announced Saim Kerman, Turkish Medicines and Medical Devices Agency – TİTCK, Turkey 14:30-15:00 Title to be announced SGK Speaker, Republic of Turkey Social Security Institution - SGK, Turkey 15:00-15:30 The impact of pharmaceutical reimbursement decisions on health indicators and health care services: Examples from Turkey and abroad Mehtap Tatar, Hacettepe University, Turkey 15:30-16:00 Pharmaceutical reimbursement system in Turkey: What has been done and what must be done in the future? Bülent Gümüşel, Hacettepe University, Turkey 16:00-16:20 Coffee Break 16:20-16:50 Future of access to medicines: for reimbursed and self-pay Abdulkadir Keskinaslan, Novartis, Switzerland / University of Washington, United States 16:50-17:10 New Approaches to Asset Pricing Models from the point of view of Decision Makers & Industry Osman Kara, Association of Research-Based Pharmaceutical Companies – AİFD, Turkey 17:10-17:30 Current status and experienced problems of pharmaceutical reimbursement Ecz. Tunç Köksal, Pharmaceutical Manufacturers Association of Turkey – İEİS, Turkey 17:30-17:50 Pharmaceutical reimbursement systems and view of a pharmacist Harun Kızılay, Turkish Pharmacists’ Association – TEB, Turkey 17:50-18:30 Panel Discussion 5 Hall A, September 9, 2014 6 08:30-09:15 Opportunities and challenges for design and development of anticancer nanomedicines Ruth Duncan-Plenary Lecture, Cardiff University, United Kingdom 09:15-09:45 Opportunities offered by nanotechnology in topical drug delivery Carla Caramella, University of Pavia, Italy 09:45-10:15 Physicochemical characteristics of polymer based drug delivery systems: the influence on formulation process and on drug release Sasa Baumgartner, University of Ljubljana, Slovenia 10:15-10:45 Targeting nanomedicines to epithelial barriers - intestines, skin and lung Claus-Michael Lehr, Saarland University, Germany 10:45-11:00 Coffee Break 11:00-11:30 Recent nano medical system developed with PLGA nano particulate platform Yoshiaki Kawashima, Aichi Gakuin University, Japan 11:30-12:00 Strategic approach for the PEGylation of GLP-1 analogues Kang Choon Lee, Sungkyunkwan University, South Korea 12:00-12:30 “Green” nanomedicine using “cage” nanoassemblies Ruxandra Gref, University of Paris-Sud, France 12:30-14:00 Lunch 14:00-14:30 Polymeric nanoparticles for targeted drug delivery Wim E. Hennink, Utrecht University, The Netherlands 14:30-15:00 Noninvasive in vivo monitoring of Nano-DDS: distribution, stimulus-sensitive release and therapeutic efficiency Karsten Maeder, Martin-Luther - University of Halle, Germany 15:00-15:30 Nanodrugs: pharmacokinetics and safety Satomi Onoue, University of Shizuoka, Japan 15:30-15:45 Coffee Break 15:45-16:15 Dissolution perspectives for nanotechnology products Susan D’Souza, Sunovion Pharm Inc., United States 16:15-16:45 Non-toxic solvent-based nanoparticle engineering for drug delivery Alf Lamprecht, University of Bonn, Germany 16:45-17:00 Oral Presentation-4 17:00-17:15 Oral Presentation-5 17:15-17:30 Oral Presentation-6 Hall B, September 9, 2014 09:15-09:45 Biotechnology and biosimilar products Hüseyin Yılmaz, Turkish Medicines and Medical Devices Agency – TİTCK, Turkey 09:45-10:15 Biosimilars: challenges and opportunities Filiz Öner, Hacettepe University, Turkey 10:15-10:45 Biotech product development, manufacturing and analytical technology Anthony Mire-Sluis, Amgen Inc., United States 10:45-11:00 Coffee Break 11:00-11:30 Biobetter : the past and the future of the long-acting drug Young-Chul Sung, Pohang University of Science and Technology, South Korea 11:30-12:00 Biosimilars and noncomparables Sundar Ramanan, Amgen Inc., United States 12:00-12:30 Manufacturing of vaccines - new trends Tom Sam, Merck Sharp & Dohme (R.), The Netherlands 12:30-14:00 Lunch 14:00-14:30 Analysis, quality control and methods for determining counterfeit drug products in Turkey Yücel Dener, Turkish Medicines and Medical Devices Agency-TİTCK, Turkey 14:30-15:00 Regulatory perspective of biotech products Virginia Acha, Amgen Inc., United States 15:00-15:45 Biosimilars: Turkish regulatory aspect R. Neslihan Gürsoy, Hacettepe University, Turkey 15:45-16:00 Coffee Break 16:00-16:30 Focus on biosimilar development İrem Yenice, Sanovel Pharmaceuticals, Turkey 16:30-16:50 Current status and future directions of biotechnological and biosimilar drugs in Turkey Hasan Ersin Zeytin, Pharmaceutical Manufacturers Association of Turkey - İEİS, Turkey / Nobel Pharma, Turkey 16:50-17:10 Biotechnological drug manufacturing and effects to Turkish economy Cem Koçak, Pharmaceutical Industry Association of Turkey- TİSD, Turkey 7 Hall A, September 10, 2014 8 08:30-08:45 Introduction and overview of drug-device combination products Sema Çalış, Hacettepe University, Turkey 08:45-09:15 Medical devices and CE certification time course from the perspective of medical device regulations Memnune Boşgelmez, Turkish Medicines and Medical Devices Agency - TİTCK, Turkey 09:15-09:45 Title to be announced Cem F. Bozkurt, Alvimedica Medical Devices, Turkey 09:45-10:00 Coffee Break 10:00-10:30 Therapeutic ability of orthopaedic implant technology is challenging biologic repair by tissue engineering Bülent Atilla, Hacettepe University, Turkey 10:30-11:00 CE marking – changing & evolving requirements Gert Bos, BSI Healthcare, United Kingdom 11:00-11:30 New developmental and regulatory aspects of drug/device combination products Tom Sam, Merck Sharp & Dohme (R.), The Netherlands 11:30-12:00 Title to be announced Sabina L. Hoekstra-van den Bosch, Philips Healthcare, The Netherlands 12:00-14:00 Lunch 14:00-14:30 Ideal Inhaler device design and importance of inhaler device selection for clinicians Can Öztürk, Gazi University, Turkey 14:30-15:00 The responsibility of stakeholders for safety of medical devices Kemal Tekin, University of Turkish Aeronautical Association, Turkey 15:00-15:30 The challenge in medical devices from R&D to application: Adventure of a cardiovascular stent Kemal Tekin, University of Turkish Aeronautical Association, Turkey 15:30-16:00 National academic R&D grants Demet Daşkın, TÜBİTAK-The National and Technological Research Council of Turkey, Turkey 16:00-16:30 Closing Ceremony Hall B, September 10, 2014 08:45-09:15 The Inhalation Products: Implementations of Turkish Ministry of Health Turkish Medicines and Medical Devices Agency Fatma Bilgen Beldüz, Turkish Medicines and Medical Devices Agency – TİTCK, Turkey 09:15-09:45 Prediction of aerosol delivery from pharmaceutical dry powder inhalers Anthony J. Hickey, Research Triangle Institute, United States 09:45-10:15 Marketing authorization of dry powder inhalers Anne Gayot, University of Lille, France 10:15-10:45 Understanding powder processing: the key to inhalation drug product development Hartwig Steckel, Christian Albrecht University of Kiel, Germany 10:45-11:00 Coffee Break 11:00-11:30 cGMP for DPI Products : How to ensure prevention of cross-contamination Oliver Schlaefli, Novartis, Switzerland 11:30-12:00 Drug nanoparticles: Production, dissolution, and pulmonary drug delivery Philip Chi Lip Kwok, The University of Hong Kong, Hong Kong 12:00-12:30 Current and future DPI products Farhad Farshi, Pharmaceutical Manufacturers Association of Turkey- İEİS, Turkey / Abdi İbrahim Pharmaceuticals, Turkey 12:30-14:00 Lunch 9 10 11 12 13 14 15